发明名称 Polyol and polyether iron oxide complexes as pharmacological and/or MRI contrast agents
摘要 Iron oxide complexes, pharmacological compositions and unit dosage thereof, and methods for their administration, of the type employing an iron oxide complex with a polyol, are disclosed. The pharmacological compositions employ a polysaccharide iron oxide complex, wherein the polysaccharide is a modified polyol such as a carboxyalkylated reduced dextran. The complex is stable to terminal sterilization by autoclaving. The compositions are suitable for parenteral administration to a subject for the treatment of iron deficiencies or as MRI contrast agent. The complex is substantially immunosilent, provide minimal anaphylaxis and undergo minimal dissolution in vivo. The pharmacological compositions of the complex contain minimal free iron which can be quantified by a variety of methods.
申请公布号 US9555133(B2) 申请公布日期 2017.01.31
申请号 US201313937923 申请日期 2013.07.09
申请人 AMAG Pharmaceuticals, Inc. 发明人 Groman Ernest V.;Paul Kenneth G.;Frigo Timothy B.;Bengele Howard;Lewis Jerome M.
分类号 A61B5/055;A01N43/04;A61K31/715;A61K49/12;A61K47/48;A61K49/18;B82Y5/00;A61K9/14;A61K33/26;A61K47/36 主分类号 A61B5/055
代理机构 Goodwin Procter LLP 代理人 Goodwin Procter LLP
主权项 1. A method of making an autoclavable carboxymethylated reduced dextran iron oxide complex intended for administration by injection to a mammalian subject, the method comprising the steps of: (i) reacting a dextran with a borohydride salt, or hydrogen in the presence of a hydrogenation catalyst, to produce a reduced dextran; (ii) carboxymethylating the reduced dextran to produce a carboxymethylated reduced dextran; (iii) complexing the carboxymethylated reduced dextran with an iron salt to produce a carboxymethylated reduced dextran iron oxide complex; and (iv) sterilizing the carboxymethylated reduced dextran iron oxide complex by autoclaving; the complexing comprising contacting the carboxymethylated reduced dextran with a mixture of ferric and ferrous salts, cooling the resulting solution and adding ammonium hydroxide to neutralize the solution and recovering the carboxymethylated reduced dextran iron oxide complex; such complex being stable at a temperature of at least about 121° C. for a period effective to sterilize the complex; wherein the autoclavable carboxymethylated reduced dextran iron oxide complex has a particle size of 10 nm to 50 nm.
地址 Waltham MA US